About: Alexion Pharmaceuticals   Goto Sponge  NotDistinct  Permalink

An Entity of Type : yago:WikicatCompaniesListedOnNASDAQ, within Data Space : covidontheweb.inria.fr associated with source document(s)

Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became an independent subsidiary of AstraZeneca in 2021. With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.

AttributesValues
type
label
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals
  • 瑞颂制药
comment
  • Alexion Pharmaceuticals est une entreprise de biotechnologie américaine spécialisée dans la recherche et le développement de produits thérapeutiques destinés au traitement des maladies hématologiques et cardiovasculaires, des maladies auto-immunes et des cancers et produisant notamment l'Éculizumab, un anticorps. Elle est basée à Cheshire, au Connecticut. Elle est cotée en bourse : Nasdaq Stock Market - Nasdaq Global Select Market - Nasdaq 100 et SP 500
  • Alexion Pharmaceuticals (NASDAQ: ALXN) é uma empresa farmaceutica americana, sediada em Connecticut.
  • Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became an independent subsidiary of AstraZeneca in 2021. With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.
  • 瑞颂制药(英語:Alexion Pharmaceuticals Inc.),也譯為亚力兄制药,是一家美國製藥公司,以發明治療及陣發性夜間血紅素尿症的藥物而出名,此外也開發其他針對免疫系統疾病的藥物。
  • Alexion Pharmaceuticals è un'azienda farmaceutica statunitense con sede a Boston, in Massachusetts, specializzata in farmaci orfani per il trattamento di malattie rare. I suoi prodotti includono eculizumab (Soliris) e (Ultomiris), rispettivamente con un fatturato di 4,064 e di 1,076 miliardi di dollari nel 2020 ed entrambi utilizzati per il trattamento dei rari disturbi della sindrome emolitico-uremica atipica (SEUa) e dell'emoglobinuria parossistica notturna (EPN). Produce inoltre la asfotase alfa (Strensiq) con 731 milioni di dollari di ricavi nel 2020, utilizzata per il trattamento dell'ipofosfatasia, la sebelipasi alfa (Kanuma) con un fatturato di 117 milioni di dollari nel 2020, utilizzata per il trattamento del deficit di lipasi acida lisosomiale e l'andexanet alfa (Andexxa) con 78
  • Alexion Pharmaceuticals is een Amerikaans farmaceutisch bedrijf gespecialiseerd in weesgeneesmiddelen voor zeldzame aandoeningen. Sinds 21 juli 2021 is het een bedrijfsonderdeel van AstraZeneca.
  • Alexion Pharmaceuticals ist ein biopharmazeutisches Unternehmen mit Sitz in Boston. Das Unternehmen ist auf Arzneimittel zur Behandlung von seltenen und sehr seltenen Krankheiten spezialisiert (Orphan-Arzneimittel).
  • Alexion Pharmaceuticals — американська компанія виробник та розробник препарату соліріс англ. Soliris (Екулізумаб англ. eculizumab), що призначений для лікування рідкісних хронічних генетичних станів (пароксизмальної нічної гемоглобінурії), які можуть пошкодити нирки, серце, мозок. У США вартість річного курсу лікування складає 440 тисяч доларів США.
sameAs
name
  • Alexion Pharmaceuticals, Inc.
name
  • Alexion Pharmaceuticals
  • Alexion Pharmaceuticals, Inc.
topic
depiction
  • External Image
described by
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software